GLP-1 Comparison Guide: Semaglutide vs Tirzepatide vs Liraglutide [2026]

Medically reviewed by Dr. Michael Torres, MD - Written by the FormBlends Medical Team - Last updated March 25, 2026

Clinical review by Dr. Sarah Chen, PharmD

If you are considering a GLP-1 receptor agonist for weight loss or type 2 diabetes management, you have likely encountered three names repeatedly: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda). All three belong to the incretin-based therapy family, but they differ in meaningful ways that affect your results, your experience, and your wallet.

This guide provides a thorough, data-driven comparison of all three medications. We will analyze clinical trial data, compare side effect profiles, break down costs, discuss insurance realities, and provide decision frameworks to help you and your healthcare provider make an informed choice. Every claim in this guide is supported by published research, and we present the data objectively without favoring one medication over another.

Whether you are starting GLP-1 therapy for the first time, considering a switch from one medication to another, or simply researching your options, this is the comprehensive resource you need. For foundational information on the GLP-1 class, see our complete GLP-1 medications guide.

Who This Guide Is For

This comparison guide is designed for several audiences. If you are a patient who has been prescribed a GLP-1 medication and wants to understand how it compares to alternatives, this guide provides the data you need to have an informed conversation with your provider. If you are choosing between semaglutide and tirzepatide for the first time, the decision framework and comparison tables will help clarify the trade-offs. If you have been on one medication and are considering switching, the switching section provides practical dose conversion guidance and what to expect during the transition.

Healthcare providers may also find this guide useful as a patient education resource. The clinical trial summaries, side effect comparison tables, and decision frameworks are designed to be shared and discussed during clinical encounters. We have prioritized accuracy, balance, and citation of primary sources throughout.

This guide complements several other resources in our library. For readers who want foundational knowledge about what GLP-1 medications are and how they work, we recommend starting with our complete GLP-1 medications guide. For deep dives into specific medications, see our semaglutide guide and semaglutide dosage guide. For safety-focused information, our GLP-1 safety guide provides comprehensive coverage. For cost and access strategies, our GLP-1 cost guide covers every option.

A note on terminology: throughout this guide, we use both generic names (semaglutide, tirzepatide, liraglutide) and brand names (Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, etc.) depending on context. Generic names are used when discussing the active compound and its pharmacology. Brand names are used when discussing specific FDA-approved products, insurance coverage, and pricing. The same active ingredient may appear under multiple brand names depending on the indication (diabetes vs. weight management) and dose.

---

Head-to-Head Overview - The Key Differences at a Glance

Before diving into the details, let us establish the big picture. The following master comparison table provides a snapshot of the three medications across the dimensions that matter most. This is the single most important table in this guide, and you may want to bookmark it for quick reference.

Master Comparison Table

Quick Decision Framework

If you need a fast answer, here is the simplified guidance. We will expand on each of these considerations throughout this guide:

• Maximum weight loss potential: Tirzepatide (Zepbound/Mounjaro) has the highest average weight loss in clinical trials.
• Longest track record and most data: Semaglutide (Wegovy/Ozempic) has the most published research, including cardiovascular outcome data.
• Lowest brand-name cost: Zepbound (tirzepatide) is slightly less expensive than Wegovy at list price.
• Lowest compounded cost: Semaglutide compounding is widely available and typically the least expensive option.
• Heart disease or high CV risk: Semaglutide, based on SELECT trial data.
• Daily dosing preference: Liraglutide (Saxenda) is the only daily option.
• Type 2 diabetes focus: Both semaglutide and tirzepatide are excellent; tirzepatide may have a slight edge in A1C reduction.
• Oral option available now: Semaglutide (Rybelsus, currently for diabetes).

Now, let us go deeper into each dimension.

---

How Each Medication Works - Mechanism Comparison

Understanding how these medications work at the biological level helps explain their different efficacy profiles and side effects. While all three are classified under the GLP-1 umbrella, their mechanisms are not identical, and those differences have real clinical consequences.

Semaglutide - Pure GLP-1 Receptor Agonist

Semaglutide is a modified version of human glucagon-like peptide-1 (GLP-1), a hormone naturally produced in your gut after eating. The modifications - specifically, an amino acid substitution at position 8, an 18-carbon fatty acid chain attached via a linker, and albumin binding - dramatically extend its half-life from the natural hormone's 2-3 minutes to approximately 7 days. This is what enables once-weekly dosing.

When semaglutide binds to GLP-1 receptors, it triggers several physiological responses:

• Appetite suppression: GLP-1 receptors in the hypothalamus and brainstem reduce hunger and increase feelings of fullness. This is the primary mechanism behind weight loss.
• Delayed gastric emptying: Food moves more slowly through the stomach, contributing to satiety after smaller meals. This effect is most pronounced during initial treatment and may attenuate somewhat over time.
• Enhanced insulin secretion: When blood glucose is elevated, GLP-1 receptor activation stimulates insulin release from pancreatic beta cells. This is glucose-dependent, meaning it primarily works when blood sugar is high, reducing hypoglycemia risk compared to sulfonylureas or exogenous insulin.
• Suppressed glucagon secretion: Glucagon, a hormone that raises blood sugar, is reduced when glucose levels are elevated. This dual action on insulin and glucagon creates a powerful glucose-lowering effect.
• Possible direct metabolic effects: Emerging research suggests GLP-1 agonists may have direct effects on fat tissue, liver function, and inflammation beyond their appetite-reducing properties. GLP-1 receptors have been identified in the heart, kidneys, and immune cells, suggesting wide-ranging effects.

Semaglutide has approximately 94% amino acid homology with native human GLP-1. Its structural modifications give it strong binding affinity to the GLP-1 receptor and resistance to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which rapidly breaks down natural GLP-1. The albumin-binding fatty acid chain also protects against renal clearance, contributing to the long half-life.

For a deeper exploration of semaglutide specifically, see our dedicated semaglutide weight loss guide.

Tirzepatide - Dual GIP/GLP-1 Receptor Agonist (Why Dual Matters)

Tirzepatide is fundamentally different from semaglutide and liraglutide because it activates two receptors, not one. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This is not just a marketing distinction - it represents a genuinely different pharmacological approach that appears to produce meaningfully different clinical outcomes.

Tirzepatide is based on the native GIP sequence with modifications that also enable it to bind and activate GLP-1 receptors. The molecule includes a C20 fatty acid moiety that allows albumin binding, extending its half-life to approximately 5 days and enabling weekly dosing. tirzepatide has approximately five times greater affinity for the GIP receptor than the GLP-1 receptor, suggesting the GIP component is not merely additive but a primary driver of its effects.

The GIP component adds mechanisms that semaglutide does not have:

• GIP receptor activation in adipose tissue: GIP receptors are found on fat cells, and their activation appears to improve fat metabolism and energy expenditure. In preclinical studies, GIP receptor agonism enhanced fat oxidation, reduced fat storage, and improved lipid handling. This direct effect on fat tissue may partly explain the greater weight loss observed with tirzepatide.
• Complementary appetite regulation: GIP and GLP-1 work on overlapping but distinct neural circuits in the brain. GIP receptors are present in the hypothalamus, and their activation influences food reward pathways. Activating both pathways simultaneously may produce more strong appetite suppression than either alone, particularly by reducing both homeostatic hunger and hedonic (pleasure-driven) eating.
• Enhanced insulin secretion: Both GIP and GLP-1 stimulate insulin release, but through partially different intracellular signaling pathways in beta cells. The combined effect appears to be at least additive and potentially combined, contributing to the superior glucose control observed in the SURPASS trials. GIP is responsible for approximately 50-70% of the incretin effect in healthy individuals.
• Possible effects on energy expenditure: Some data suggest dual receptor activation may partially offset the metabolic adaptation (reduction in resting metabolic rate) that typically accompanies significant weight loss. If confirmed, this would be a meaningful advantage, as metabolic adaptation is one reason weight loss plateaus occur.
• Improved lipid metabolism: GIP receptor activation may directly improve triglyceride clearance and lipid handling independent of weight loss, contributing to cardiovascular metabolic benefits.

The dual mechanism likely explains why tirzepatide produces greater average weight loss than semaglutide in clinical trials. It is not simply a stronger version of the same drug - it is a qualitatively different pharmacological approach that engages additional biological pathways.

One complexity worth noting: the role of GIP in metabolic health has been debated in the scientific literature for decades. Historically, GIP was associated with fat storage and even obesity promotion. The apparent paradox that a GIP agonist promotes weight loss is thought to relate to several factors: the difference between physiological and supraphysiological GIP exposure, the combined effect with simultaneous GLP-1 activation, possible desensitization of adipose GIP receptors at high doses leading to a functional antagonist effect, and the complex dose-response relationships in different tissues. This remains an active and fascinating area of research that will likely yield further insights as tirzepatide use expands.

Liraglutide - First-Generation GLP-1 Agonist

Liraglutide was the first GLP-1 receptor agonist approved for weight management (as Saxenda in December 2014) and remains an important option in the GLP-1 space. Like semaglutide, it is a modified analog of human GLP-1 with 97% amino acid homology to the native hormone.

Liraglutide's structural modification - a 16-carbon fatty acid chain (palmitic acid) attached at position 26 via a glutamic acid spacer - enables albumin binding that extends its half-life to approximately 13 hours. This is significantly longer than native GLP-1 (2-3 minutes) but much shorter than semaglutide's 7-day half-life, which is why liraglutide requires daily injection rather than weekly administration.

The pharmacological actions of liraglutide are essentially the same as semaglutide - appetite suppression, delayed gastric emptying, enhanced insulin secretion, and glucagon suppression - because both work through the same GLP-1 receptor. The key differences are quantitative rather than qualitative:

• Lower receptor occupancy: Liraglutide achieves lower peak and average GLP-1 receptor occupancy than semaglutide at their respective maximum doses, which correlates with its more modest efficacy for weight loss. The receptor binding kinetics and residence time are different, with semaglutide showing slower receptor dissociation.
• Daily dosing pharmacokinetic pattern: The daily injection creates a more consistent but lower-amplitude drug level throughout the day, avoiding the peak-and-trough pattern of weekly injections. Some patients find this produces more consistent hour-to-hour appetite control, though the overall magnitude of appetite suppression is less than semaglutide.
• Faster titration: Liraglutide can be titrated to its full dose of 3.0 mg in as little as 5 weeks (increasing by 0.6 mg per week), versus 16-20 weeks for semaglutide or tirzepatide. This means patients reach their therapeutic dose faster and can assess response earlier.
• More granular dose adjustment: The 0.6 mg dose increments allow finer adjustment of the dose to balance efficacy and side effects. Some providers use liraglutide at intermediate doses (e.g., 1.8 mg or 2.4 mg) when 3.0 mg is not tolerated.

Liraglutide was approved for diabetes (as Victoza, 1.8 mg) in 2010 and for weight management (as Saxenda, 3.0 mg) in December 2014, giving it the longest track record of any GLP-1 medication for weight loss. This extensive real-world experience - now exceeding a decade - including safety data in adolescents (ages 12-17), is one of its enduring advantages when providers and patients value a well-established safety profile.

Why Mechanism Matters for You

Understanding these mechanistic differences is not just academic - it has practical implications for your treatment:

• If you plateau on one medication, switching to a different mechanism may help. Patients who plateau on semaglutide sometimes respond to tirzepatide because of the added GIP receptor activation, and vice versa. The different receptor engagement profiles mean that non-response to one does not predict non-response to the other.
• Side effect profiles relate to mechanism. GI side effects are primarily GLP-1-mediated, so all three medications cause them. However, the GIP component may modulate some of these effects differently, and the daily vs. weekly dosing patterns affect the timing and intensity of side effects.
• The dual mechanism may provide additional metabolic advantages. If you have significant insulin resistance, metabolic syndrome, or type 2 diabetes, tirzepatide's dual pathway may offer metabolic benefits - particularly in glucose control and lipid management - that extend beyond what the GLP-1 pathway alone provides.
• Future medications build on these mechanisms. Understanding GLP-1 and GIP action helps you interpret news about triple agonists (retatrutide adds glucagon receptor activation), amylin co-agonists (CagriSema), and other pipeline medications discussed later in this guide.

To summarize the mechanism comparison: semaglutide and liraglutide both work through the same receptor but differ dramatically in potency and duration of action. Tirzepatide introduces a fundamentally different pharmacological strategy by engaging two receptors simultaneously. These differences are not marketing distinctions - they translate into measurable differences in clinical outcomes that affect your weight loss trajectory, metabolic health, and side effect experience.

One area of ongoing scientific interest is whether the different receptor profiles affect body composition differently. Preliminary data suggests tirzepatide may promote a more favorable ratio of fat loss to lean mass loss, potentially due to GIP receptor effects on adipose tissue metabolism. If confirmed in larger studies, this would be a meaningful differentiator, particularly for older patients and those concerned about sarcopenia. The body composition question is being studied in dedicated imaging sub-studies within the SURMOUNT program and will provide more definitive answers as data matures.

Another important mechanistic consideration is tachyphylaxis - the phenomenon where the body becomes partially tolerant to a drug's effects over time. Some patients on semaglutide report that appetite suppression diminishes after 6-12 months on a stable dose, potentially reflecting partial receptor desensitization. Whether this occurs to the same degree with tirzepatide's dual-receptor approach is not yet clear. The two-receptor strategy may provide some resilience against single-pathway tachyphylaxis, but this remains theoretical pending long-term comparative data. This question has practical implications: if you experience diminishing appetite suppression on one medication, switching to the other may provide renewed benefit through a different receptor engagement pattern.

---

Efficacy Comparison - Weight Loss Results

This is the section most people want to see first, and rightfully so. How much weight can you actually expect to lose on each medication? We will present the clinical trial data, discuss head-to-head comparisons, and address the critical gap between trial results and real-world outcomes.

An important caveat before we begin: most of the data we are comparing comes from separate clinical trials, not direct head-to-head studies. Different trials have different patient populations, inclusion criteria, diet and exercise counseling intensity, and durations. True head-to-head data is limited but growing. We will call out where direct comparisons exist and where we are comparing across trials.

Semaglutide Clinical Data (STEP Trials: 14.9-16.9% Weight Loss)

The evidence base for semaglutide in weight management comes primarily from the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program, one of the most comprehensive trial series ever conducted for a weight loss medication. The STEP program has enrolled over 10,000 participants across multiple trials spanning different populations and study designs.

STEP 1 - the landmark trial - enrolled 1,961 adults with BMI of 30 or higher (or BMI 27 or higher with at least one weight-related complication) without diabetes. Participants received semaglutide 2.4 mg weekly or placebo, plus lifestyle intervention consisting of counseling on a 500-calorie deficit diet and 150 minutes of weekly physical activity. At 68 weeks:

• Average weight loss: 14.9% of body weight (vs. 2.4% with placebo)
• 86.4% of participants lost at least 5% of body weight
• 69.1% lost at least 10%
• 50.5% lost at least 15%
• 32.0% lost at least 20%
• Mean absolute weight loss was approximately 15.3 kg (33.7 lbs)

STEP 2 - in adults with type 2 diabetes and BMI 27 or higher - showed 9.6% average weight loss at 68 weeks with semaglutide 2.4 mg. The lower results in diabetes patients is consistent across all GLP-1 medications and is thought to relate to the metabolic effects of diabetes itself, concurrent diabetes medications, and physiological differences in appetite regulation in this population.

STEP 3 - combining semaglutide 2.4 mg with intensive behavioral therapy (30 counseling sessions over 68 weeks, with meal replacements during the first 8 weeks) - showed 16.0% weight loss at 68 weeks, demonstrating that structured lifestyle intervention meaningfully enhances pharmacological results. This trial highlights that medication and lifestyle are not either/or propositions but combined approaches.

STEP 4 - a withdrawal-design study where all participants received semaglutide for 20 weeks, then were randomized to continue or switch to placebo - showed that those who continued semaglutide lost an additional 7.9% body weight from week 20 to week 68, while those switched to placebo regained 6.9%. This trial provided important evidence about the need for continued treatment to maintain weight loss.

STEP 5 - a 104-week (2-year) extension - showed 15.2% weight loss maintained at 2 years, confirming the durability of semaglutide's effects with continued treatment. Weight loss plateaued around week 60 but was maintained through week 104.

STEP 8 - directly compared semaglutide to liraglutide and showed semaglutide was significantly superior (detailed in the head-to-head section below).

For a comprehensive review of all STEP trial data, see our semaglutide weight loss guide.

Tirzepatide Clinical Data (SURMOUNT Trials: 20.9-22.5% Weight Loss)

The tirzepatide weight management evidence comes from the SURMOUNT trial program, which demonstrated unprecedented weight loss numbers for a pharmaceutical intervention. These results shifted clinical expectations about what pharmacotherapy can achieve.

SURMOUNT-1 - the important trial - enrolled 2,539 adults with BMI of 30 or higher (or BMI 27 or higher with complications) without diabetes. Participants received tirzepatide at 5 mg, 10 mg, or 15 mg weekly, or placebo, plus lifestyle intervention. At 72 weeks:

• Average weight loss at 5 mg: 15.0% (comparable to semaglutide 2.4 mg)
• Average weight loss at 10 mg: 19.5%
• Average weight loss at 15 mg: 20.9%
• Placebo: 3.1%
• At 15 mg: 90.9% lost at least 5%, 78.9% lost at least 10%, 66.6% lost at least 15%, 57.0% lost at least 20%
• Mean absolute weight loss at 15 mg was approximately 23.6 kg (52 lbs)

The 15 mg results are remarkable: more than half of all participants lost at least 20% of their body weight, a threshold previously achievable only through bariatric surgery. The range of results also highlights the dose-response relationship - the 5 mg dose of tirzepatide produces results similar to maximum-dose semaglutide, while the 10 mg and 15 mg doses go substantially further.

SURMOUNT-2 - in adults with type 2 diabetes and BMI 27 or higher - showed 12.8% (10 mg) and 14.7% (15 mg) weight loss at 72 weeks, substantially exceeding semaglutide's results in the diabetic population (STEP 2: 9.6%). The A1C reduction was also impressive, with mean reductions of 2.1% (10 mg) and 2.3% (15 mg).

SURMOUNT-3 - combining tirzepatide with intensive behavioral therapy, including an initial 12-week low-calorie diet lead-in period - showed 26.6% weight loss at the maximum tolerated dose over 72 weeks, the highest average weight loss ever reported in a major pharmaceutical trial. This suggests that when combined with aggressive lifestyle intervention, tirzepatide can approach the weight loss magnitude of some bariatric surgical procedures.

SURMOUNT-4 - a withdrawal-design study similar to STEP 4 - demonstrated that participants who stopped tirzepatide after 36 weeks regained about half the weight they had lost over the next year, while those who continued lost additional weight, for a total of 21.4% at 88 weeks. This confirms, as with semaglutide, that continued treatment is necessary to maintain results.

Liraglutide Clinical Data (SCALE Trials: 5-8% Weight Loss)

Liraglutide's weight management data comes from the SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) trial program, which was notable when published in 2015 but shows more modest results compared to newer agents.

SCALE Obesity and Prediabetes - the main trial - enrolled 3,731 adults with BMI of 30 or higher, or BMI 27 or higher with dyslipidemia or hypertension. At 56 weeks with liraglutide 3.0 mg daily:

• Average weight loss: 8.0% (vs. 2.6% with placebo)
• 63.2% lost at least 5%
• 33.1% lost at least 10%
• 14.4% lost at least 15%
• Mean absolute weight loss: 8.4 kg (18.5 lbs)

SCALE Diabetes - in patients with type 2 diabetes - showed 6.0% average weight loss at 56 weeks.

SCALE Maintenance - in patients who had lost at least 5% of body weight through caloric restriction before starting liraglutide - showed that liraglutide helped maintain and extend initial weight loss, with an additional 6.2% weight loss over 56 weeks compared to 0.2% with placebo.

While these numbers are lower than semaglutide and tirzepatide, they were considered clinically meaningful at the time and remain so. A 5-10% body weight reduction produces significant improvements in blood pressure (average 5 mmHg systolic reduction), fasting glucose and A1C, cholesterol and triglycerides, sleep apnea severity, joint pain and mobility, fatty liver disease markers, and overall quality of life.

The SCALE program also included a three-year extension study that showed liraglutide significantly reduced the risk of progressing from prediabetes to type 2 diabetes - a preventive benefit that adds to its clinical value.

Head-to-Head Trial Data

Direct comparisons between these medications are limited but illuminate real differences:

STEP 8: Semaglutide vs. Liraglutide (Direct Comparison)

This 68-week randomized controlled trial directly compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily in 338 adults without diabetes. The results were unambiguous:

• Semaglutide group: 15.8% weight loss
• Liraglutide group: 6.4% weight loss
• Estimated treatment difference: 9.4 percentage points in favor of semaglutide
• Semaglutide produced approximately 2.5 times more weight loss than liraglutide
• More semaglutide participants achieved 10%, 15%, and 20% weight loss thresholds at every time point

This trial settled the question of whether semaglutide is superior to liraglutide for weight loss - it clearly is, by a substantial margin. The GI side effect profiles were comparable, meaning the greater efficacy of semaglutide does not come at the cost of significantly worse tolerability.

SURPASS-2: Tirzepatide vs. Semaglutide (Diabetes Population)

This 40-week trial compared tirzepatide (5, 10, 15 mg) to semaglutide 1 mg (the diabetes dose, not the 2.4 mg weight loss dose) in 1,879 adults with type 2 diabetes. Tirzepatide at all three doses was statistically superior to semaglutide 1 mg for both A1C reduction and weight loss:

• Tirzepatide 5 mg: 7.6 kg weight loss, 2.01% A1C reduction
• Tirzepatide 10 mg: 9.3 kg weight loss, 2.24% A1C reduction
• Tirzepatide 15 mg: 11.2 kg weight loss, 2.30% A1C reduction
• Semaglutide 1 mg: 5.7 kg weight loss, 1.86% A1C reduction

A critical limitation: SURPASS-2 used semaglutide at 1 mg (the Ozempic diabetes dose), not the 2.4 mg Wegovy weight loss dose. This makes the comparison informative for diabetes management but less definitive for weight loss specifically. A true head-to-head comparison of maximum weight loss doses (semaglutide 2.4 mg vs. tirzepatide 15 mg) has not yet been published, though clinical trials are in progress. Based on cross-trial comparison, tirzepatide 15 mg likely retains an advantage, but the magnitude of difference may be smaller than comparing STEP 1 to SURMOUNT-1 suggests.

Clinical Trial Results Summary Table

Real-World Results vs Clinical Trial Numbers

Clinical trial results represent a best-case scenario. Participants receive regular monitoring, structured dietary counseling, frequent check-ins that reinforce accountability, and the motivation that comes from being in a research study. Real-world outcomes are typically more modest, and it is important to set realistic expectations.

Real-world data published in 2024 and 2025 provides a clearer picture:

• Semaglutide real-world weight loss: Approximately 10-13% at one year, roughly 75-85% of clinical trial results. A large retrospective study of over 18,000 patients published in JAMA Network Open found 12.3% weight loss at 12 months in a real-world population. A separate Veterans Affairs database analysis found similar results at 10.5% in a population with more comorbidities.
• Tirzepatide real-world weight loss: Approximately 14-18% at one year, based on early real-world evidence from insurance claims databases and telehealth platform data. Because tirzepatide received its weight loss approval more recently (November 2023), long-term real-world data beyond one year is still accumulating.
• Liraglutide real-world weight loss: Approximately 4-6% at one year, with substantial variation. Adherence is a particularly significant challenge with daily injections, and real-world discontinuation rates at 12 months exceed 60% in some analyses.

Several factors explain the gap between trial and real-world results:

• Adherence: In real life, people miss doses, stop and restart, take drug holidays during travel, or discontinue early due to cost, side effects, or frustration with the pace of progress. Clinical trial participants have structured follow-up, regular contact with research coordinators, and greater accountability.
• Titration speed and patterns: Some real-world patients titrate faster than recommended (increasing side effects and discontinuation) or stay at sub-therapeutic doses too long due to supply issues or cost-driven dose-stretching.
• Lifestyle intervention intensity: Clinical trials typically include structured diet and exercise counseling every 4-8 weeks, often with registered dietitians or behavioral psychologists. Routine clinical practice rarely provides this level of support.
• Patient selection: Clinical trials exclude patients with certain comorbidities, medication interactions (e.g., insulin, which blunts weight loss), unstable psychiatric conditions, and other factors that are common in real-world populations.
• Duration of treatment: Many real-world patients discontinue before reaching the 12-18 month time point at which maximum results are seen in trials. Insurance coverage gaps, cost, and side effects are common reasons for early discontinuation.

The takeaway: expect roughly 75-85% of the clinical trial numbers in real-world practice, and work with your provider to maximize your results through proper titration, lifestyle support, and consistent adherence.

It is also worth noting that real-world studies often use different outcome definitions. Clinical trials typically report weight loss as a percentage of baseline body weight using the intention-to-treat principle (including dropouts). Real-world studies may use completers-only analyses, different time windows, or different baseline definitions, making direct comparisons complex. When evaluating real-world data, pay attention to the analysis methodology, not just the headline numbers.

Another important real-world factor is the effect of concurrent medications. Many patients taking GLP-1 medications are also on other medications that can influence weight. For example, insulin, sulfonylureas, and certain antidepressants (mirtazapine, paroxetine) can promote weight gain and partially offset GLP-1 effects. Conversely, metformin, SGLT2 inhibitors, and topiramate may have additive weight loss benefits. Your provider should review your complete medication list and consider potential interactions when selecting and dosing a GLP-1 medication.

The concept of weight loss trajectory is also important for setting expectations. With semaglutide and tirzepatide, weight loss follows a predictable pattern: slow initial loss during the titration phase (months 1-4), accelerating loss after reaching the target dose (months 4-10), gradual deceleration (months 10-15), and eventual plateau (months 15-18). Understanding this trajectory helps prevent premature discontinuation during the early slow phase and realistic goal-setting for the maintenance phase. Patients who understand this pattern are more likely to persist through the titration phase and reach the period of maximum benefit.

For patients with higher starting BMI (40+), absolute weight loss in pounds may be impressive even if the percentage is somewhat lower. For example, a patient starting at 320 lbs who loses 15% on semaglutide loses 48 lbs - a clinically meaningful result that significantly improves health markers even though a patient starting at 220 lbs might lose a higher percentage. The clinical significance of weight loss should be evaluated in the context of individual starting weight, comorbidity improvement, and quality of life gains, not solely by percentage targets.

Who Responds Best to Each Medication

Individual variation in response to GLP-1 medications is substantial - more than most patients realize. In every clinical trial, there is a wide spread of outcomes. Some participants lose 25-30% of their body weight while others on the same medication and dose lose less than 5%. Understanding the factors that predict response can help guide medication selection.

Likely stronger responders to semaglutide:

• Patients whose primary driver is appetite, food preoccupation, and snacking between meals - semaglutide has strong central appetite suppression via hypothalamic and brainstem GLP-1 receptors
• Patients with cardiovascular disease or high cardiovascular risk factors - SELECT trial data directly supports cardiovascular event reduction
• Patients who want an established medication with the most extensive long-term published data available
• Patients who responded well to lower-dose semaglutide (Ozempic at 0.5 or 1 mg) and want to continue with a familiar mechanism at a higher dose
• Patients who prefer the most established compounded option with the widest availability and lowest compounding cost

Likely stronger responders to tirzepatide:

• Patients with significant insulin resistance or metabolic syndrome - the dual GIP/GLP-1 mechanism provides additional metabolic pathway activation that may break through insulin-resistance-mediated weight loss resistance
• Patients with type 2 diabetes seeking both weight loss and glucose control - tirzepatide showed superior A1C reduction in SURPASS trials
• Patients who plateaued on semaglutide - the added GIP receptor activation engages different biological pathways and may restart progress
• Patients seeking maximum possible weight loss who are willing to titrate to higher doses
• Patients with polycystic ovary syndrome (PCOS) or other insulin-resistance-driven conditions

Patients who may prefer liraglutide:

• Those who want finer dose control (daily dosing allows 0.6 mg incremental adjustments for a more gradual titration experience)
• Adolescents aged 12-17 - liraglutide has the most pediatric data and is FDA-approved for weight management in this age group
• Patients who experienced intolerable GI side effects with weekly medications and want to try a daily option with lower peak drug levels
• Those whose insurance covers Saxenda but not Wegovy or Zepbound
• Patients who value the longest available safety track record (approved for weight loss since 2014)

Approximately 10-15% of patients do not respond meaningfully to any given GLP-1 medication. If you lose less than 5% of body weight after 3-6 months at the full dose with good adherence, your provider may recommend switching to a different medication in the class or adding adjunct therapy. non-response to one medication does not predict non-response to another - the different mechanisms mean some patients are biologically better suited to one than the other.

---

Side Effect Comparison - What to Expect

Side effects are often the deciding factor in medication selection and continuation. All GLP-1 medications share a core side effect profile dominated by gastrointestinal symptoms, but there are meaningful differences in frequency, severity, and management between the three options. Understanding these differences helps set realistic expectations and may influence your choice. For a broader perspective on GLP-1 safety, see our comprehensive safety guide.

GI Side Effects (Nausea, Vomiting, Diarrhea - Rates by Medication)

Gastrointestinal side effects are the most common reason patients consider switching or stopping GLP-1 therapy. These effects are mediated by GLP-1 receptor activation in the gut and brainstem and are generally dose-dependent, worst during titration, and improve over time as the body adapts.

Important context for these numbers: These rates come from different clinical trials with different populations, reporting methods, and durations. Direct comparison across trials is imperfect. In the one head-to-head trial (STEP 8), semaglutide and liraglutide had very similar GI side effect rates despite semaglutide producing much more weight loss. The SURPASS-2 trial comparing tirzepatide to semaglutide 1 mg showed similar overall GI rates.

Most GI side effects peak during the first 4-8 weeks after each dose escalation and then diminish. By the time patients have been on a stable dose for 2-3 months, the majority report that nausea has resolved or become very mild. Proper slow titration is the single most effective strategy for minimizing GI side effects with any of these medications.

Injection Site Reactions

Because all three medications are administered by subcutaneous injection, localized reactions at the injection site can occur. These are generally mild and short-lived:

• Semaglutide (Wegovy/Ozempic): Injection site reactions reported in approximately 3.2% of patients. The FlexTouch pen uses a 30-gauge, 8 mm needle, which is thin and relatively painless. Reactions typically consist of mild redness or itching lasting a few hours.
• Tirzepatide (Zepbound/Mounjaro): Injection site reactions in approximately 3.2% of patients at the 5 mg dose, rising to 5.6% at 15 mg. The Lilly KwikPen uses a 31-gauge, 5 mm needle - the thinnest and shortest of the three, generally considered the least painful injection experience. However, some patients report more visible redness or small nodules at the injection site compared to semaglutide.
• Liraglutide (Saxenda): Injection site reactions in approximately 2.5% of patients, though the daily frequency means more total injections and more opportunities for cumulative irritation. Rotating injection sites (abdomen, thigh, upper arm) is particularly important with daily injections.

Fatigue and Energy Effects

Fatigue is reported by some patients on all GLP-1 medications, though it was not consistently measured as a primary outcome in clinical trials. Based on trial adverse event data and real-world reports:

• Semaglutide: Fatigue reported in approximately 11% of patients in STEP trials, compared to 5% with placebo. Most common during dose escalation. Often related to reduced caloric intake rather than a direct drug effect.
• Tirzepatide: Fatigue in approximately 7% of patients in SURMOUNT-1. Some patients report initial fatigue that resolves as the body adjusts to the dual-receptor mechanism.
• Liraglutide: Fatigue in approximately 7.5% of patients in SCALE trials. Daily dosing may produce more consistent but lower-level fatigue compared to the weekly peak-trough pattern.

Strategies to manage fatigue include ensuring adequate protein and calorie intake (avoid excessively restricting calories below 1,200 per day), staying hydrated, maintaining a regular sleep schedule, and moderating exercise intensity during dose escalation periods.

Hair Loss

Hair thinning (telogen effluvium) has been reported with all GLP-1 medications and is a significant concern for many patients, particularly women. This is generally related to the rapid weight loss itself rather than a direct drug effect - telogen effluvium occurs with any cause of significant rapid weight loss, including caloric restriction and bariatric surgery.

• Semaglutide: Hair loss reported in approximately 3% of patients in STEP trials (vs. 1% placebo). More common in patients who lose more than 15% of body weight.
• Tirzepatide: Hair loss reported in approximately 5.7% at the 15 mg dose in SURMOUNT-1 (vs. 1% placebo). The higher rate likely reflects the greater magnitude of weight loss rather than a specific drug effect.
• Liraglutide: Hair loss is reported less frequently, likely because the weight loss is less dramatic. Rates were not consistently reported in SCALE trials.

Hair loss typically begins 2-4 months after the onset of rapid weight loss and is usually temporary, resolving over 6-12 months as weight stabilizes. Ensuring adequate protein intake (at least 60-80 grams daily), taking a multivitamin with biotin and zinc, and avoiding excessively rapid weight loss through proper titration can help minimize this side effect.

Serious Risks by Medication

All three medications carry the same boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma), based on findings in rodent studies. This risk has not been confirmed in humans, and the warning is considered precautionary. All three are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Other serious but uncommon risks include:

• Pancreatitis: Reported at rates of 0.1-0.3% across all three medications. Patients should be monitored for persistent severe abdominal pain. If pancreatitis is confirmed, the medication should be discontinued permanently.
• Gallbladder disease: Cholelithiasis (gallstones) is associated with rapid weight loss from any cause. Rates were approximately 1.6% with semaglutide, 0.6% with tirzepatide, and 2.5% with liraglutide in their respective trials, all higher than placebo.
• Acute kidney injury: Reported rarely (<0.5%) and usually related to severe dehydration from vomiting or diarrhea. Adequate hydration is critical.
• Hypoglycemia: Low when used alone (all are glucose-dependent), but risk increases when combined with insulin or sulfonylureas. Tirzepatide's dual mechanism may confer slightly more hypoglycemia risk in diabetes patients on concurrent insulin, requiring insulin dose adjustments.
• Gastroparesis: Severe delayed gastric emptying is a rare but emerging concern with extended GLP-1 use. Patients with pre-existing gastroparesis should generally avoid GLP-1 medications.

Additional rare but reported side effects across the class include:

• Intestinal obstruction: Very rare reports of intestinal obstruction have been associated with GLP-1 use, potentially related to severe delayed gastric emptying. Patients with a history of bowel obstruction or adhesions should discuss this risk with their provider before starting therapy.
• Ileus: Paralytic ileus (temporary cessation of bowel motility) has been reported rarely, particularly in patients undergoing general anesthesia while on GLP-1 medications. The American Society of Anesthesiologists has issued guidance recommending consideration of GLP-1 therapy in preoperative planning, including possible dose adjustments or holding the medication before elective procedures involving anesthesia.
• Allergic reactions: Injection-site hypersensitivity and systemic allergic reactions occur very rarely (less than 0.1%). Anaphylaxis has been reported but is extremely uncommon. Patients with known hypersensitivity to the active ingredient or any excipient should not use the medication.
• Thyroid monitoring: While the C-cell tumor risk has not been confirmed in humans, many providers recommend periodic thyroid examination and monitoring calcitonin levels, particularly in patients with thyroid nodules or a family history of thyroid cancer.
• Psychiatric effects: Post-marketing surveillance has identified reports of suicidal ideation and behavior in patients taking GLP-1 medications. The FDA has investigated these reports and, as of early 2026, has not found a causal relationship. However, patients with a history of depression or suicidal thoughts should be monitored. weight loss itself can affect mood through multiple pathways, and correlation does not establish causation.
• Pregnancy considerations: All three medications should be discontinued at least 2 months before planned pregnancy (semaglutide's long half-life requires even longer washout). Animal studies showed fetal harm at high doses. There is limited human pregnancy data. Women of reproductive age should use effective contraception while on GLP-1 therapy.

The overall serious adverse event rate in clinical trials was low for all three medications, and the benefit-risk profile is considered favorable for appropriately selected patients. The most important safety strategy is proper patient selection (avoiding use in patients with contraindications), gradual dose titration, adequate hydration, and regular follow-up with your healthcare provider.

Which Has the Most Tolerable Side Effect Profile

No GLP-1 medication is clearly superior in tolerability across all dimensions. However, some general patterns emerge:

• Lowest overall GI rates in trials: Tirzepatide, possibly because the GIP component modulates nausea differently. However, tirzepatide had the highest GI-related discontinuation rate in some analyses, suggesting the GI effects, while less frequent, may be more severe when they occur.
• Best dose flexibility for side effect management: Liraglutide, because daily dosing allows 0.6 mg increments and more granular adjustment. Patients sensitive to GI side effects can titrate very slowly (e.g., 0.6 mg increments over 2-week intervals).
• Fewest injections per year: Semaglutide and tirzepatide (52 each, vs. 365 for liraglutide), which matters for injection-related anxiety and site reactions.
• Most established safety profile: Liraglutide, with over 10 years of real-world post-marketing safety data.

The most important factor in tolerability is proper titration - regardless of which medication you choose, starting at the lowest dose and increasing gradually according to the recommended schedule dramatically reduces the severity and duration of side effects.

---

Dosing Comparison - Schedules and Convenience

Dosing differences between these medications affect convenience, titration experience, and practical day-to-day use. For detailed semaglutide dosing information, see our semaglutide dosage guide.

Semaglutide Dosing (Weekly Injection, 5-Step Titration)

Semaglutide for weight management (Wegovy) follows a 5-step dose escalation over 16-20 weeks:

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.50 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance dose)

Each step can be extended by 4 additional weeks if GI side effects are problematic, so some patients may take 20 or more weeks to reach the full dose. The injection can be given on any day of the week, at any time of day, with or without food. Consistency - the same day each week - is recommended but not mandatory. If a dose is missed, it can be taken within 5 days of the missed day; otherwise, skip to the next scheduled dose.

Tirzepatide Dosing (Weekly Injection, 4-Step Titration)

Tirzepatide for weight management (Zepbound) follows a 4-step dose escalation:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5.0 mg once weekly
• Weeks 9-12: 10.0 mg once weekly
• Week 13 onward: 15.0 mg once weekly (maximum dose)

Some providers use an intermediate step at 7.5 mg (available as a Mounjaro dose strength) between 5 mg and 10 mg. Patients may remain at 5 mg or 10 mg if they achieve satisfactory results and tolerate the dose well - not everyone needs to titrate to 15 mg. Similar to semaglutide, the injection is flexible in timing and can be administered on any day, with a recommendation to maintain the same day each week.

Liraglutide Dosing (Daily Injection)

Liraglutide for weight management (Saxenda) requires daily injection with a 5-step titration over 5 weeks:

• Week 1: 0.6 mg once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 onward: 3.0 mg once daily (maintenance dose)

The daily injection can be given at any time, with or without food, but the same time each day is recommended for consistent blood levels. The shorter half-life means missed doses result in a more immediate return of appetite, making adherence more critical than with weekly medications. If you are more than 12 hours late for a dose, skip it and take the next one at the usual time.

Dosing Comparison Table

Practical Dosing Tips for All Medications

Regardless of which medication you choose, several practical strategies can optimize your dosing experience:

• Pick a consistent injection day and time. For weekly medications, choosing the same day each week helps build routine. Many patients prefer to inject on a day when they can rest if GI side effects occur - for example, Friday evening so that any nausea peaks over the weekend rather than during work days.
• Rotate injection sites. Alternate between abdomen (at least 2 inches from the navel), outer thigh, and back of the upper arm. Consistent use of the same site can cause lipodystrophy (changes in fat tissue) that affects drug absorption. Keep a simple log or rotate systematically (abdomen left, abdomen right, left thigh, right thigh).
• Allow refrigerated pens to warm slightly before injection. Cold injections can be more uncomfortable. Removing the pen from the refrigerator 15-30 minutes before injection (while staying within the room-temperature stability window) can reduce discomfort.
• Do not rub the injection site. Gentle pressure with a cotton ball or gauze for 10 seconds is sufficient. Rubbing can increase bruising and irritation.
• Set reminders. Use phone alarms, calendar reminders, or medication tracking apps. Missed doses are one of the most common reasons for suboptimal results in real-world practice. For weekly medications, some patients find it helpful to associate injection day with another weekly routine (e.g., always inject on trash day, or Sunday evening before the work week).
• Plan for travel. Injectable medications require temperature-controlled storage. For short trips, an insulated bag with a cool pack is sufficient. For air travel, keep medication in your carry-on (never checked luggage where temperatures are not controlled). TSA allows injectable medications through security with documentation. For international travel, carry a copy of your prescription and a letter from your provider.
• Understand what to do with missed doses. For semaglutide and tirzepatide: if within 5 days of the missed dose, take it as soon as you remember, then resume your regular schedule. If more than 5 days late, skip the missed dose and take the next one on schedule. For liraglutide: if more than 12 hours late, skip and take the next day's dose on schedule. Never double up on doses.

Oral Options (Rybelsus, Oral Tirzepatide Pipeline)

For patients who strongly prefer oral medication over injections, options are expanding:

Oral semaglutide (Rybelsus) is currently the only available oral GLP-1 medication. It is approved for type 2 diabetes at doses of 7 mg and 14 mg daily. The coformulation with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) enables absorption through the stomach lining. Key considerations:

• Must be taken on an empty stomach with no more than 4 ounces of plain water
• Must wait at least 30 minutes before eating, drinking, or taking other medications
• Lower bioavailability than injectable semaglutide (<1% of the oral dose is absorbed)
• At the currently approved 14 mg dose, weight loss is more modest than injectable semaglutide 2.4 mg
• Higher-dose oral semaglutide (25 mg and 50 mg) has completed Phase 3 trials showing weight loss closer to injectable semaglutide results and is expected to receive FDA approval for weight management

Oral tirzepatide is in clinical development by Eli Lilly. Early data suggests feasibility, but it has not yet reached Phase 3 trials for weight management. Given tirzepatide's larger molecular size compared to semaglutide, oral bioavailability presents additional challenges.

Orforglipron (Eli Lilly) is a small-molecule oral GLP-1 agonist (not a peptide) in Phase 3 trials. It does not require SNAC coformulation, has fewer food-timing restrictions, and may have improved oral bioavailability. Early data shows promising weight loss and A1C reduction. This could be a significant advance for patients who want oral GLP-1 therapy without the strict dosing conditions of Rybelsus.

Injection Device Comparison (Pen Types, Needle Sizes)

The injection experience varies between devices, and for patients new to self-injection, these differences can affect comfort and adherence:

• Novo Nordisk FlexTouch (semaglutide, liraglutide): A well-established pen design with audible and tactile click confirmation. The dose dial is easy to read. The Wegovy pen comes preloaded with specific doses (one pen per month at each dose level), simplifying dose selection but preventing micro-adjustments. Saxenda uses a multi-dose pen with a dial selector for dose adjustment.
• Lilly KwikPen (tirzepatide): Features a hidden needle design that many patients find less anxiety-provoking. The single-dose autoinjector format means you simply press against the skin and click - no needle is visible at any point. The 31G, 5mm needle is the smallest of the three, generally providing the most comfortable injection. The KwikPen also has a clear viewing window to confirm the injection is complete.

For all branded injectable medications, the injection process takes less than 15 seconds and most patients report that the actual injection is virtually painless after the first few uses. Compounded versions may use different delivery systems (typically insulin syringes or vials with separate needles), which require slightly more manual preparation but offer dose flexibility.

---

Cost Comparison - The Real Numbers

Cost is frequently the decisive factor in GLP-1 medication selection and access. The pricing space is complex, with wide variation depending on whether you use brand-name products, compounded versions, or have insurance coverage. For a detailed breakdown of GLP-1 costs and savings strategies, see our complete GLP-1 cost guide.

Brand-Name Pricing (Wegovy, Zepbound, Saxenda, Ozempic, Mounjaro)

Brand-name list prices as of March 2026:

• Wegovy (semaglutide 2.4 mg): Approximately $1,349 per month ($16,188 per year) at list price. This is a single-dose prefilled pen dispensed as a 4-week supply.
• Ozempic (semaglutide up to 2.0 mg, diabetes): Approximately $935 per month ($11,220 per year). Often prescribed off-label for weight loss at a lower cost than Wegovy, though at a lower maximum dose.
• Zepbound (tirzepatide, weight loss): Approximately $1,059 per month ($12,708 per year). Eli Lilly has positioned Zepbound at a lower list price than Wegovy, and has also introduced direct-to-consumer vial options at reduced pricing for patients paying out of pocket.
• Mounjaro (tirzepatide, diabetes): Approximately $1,023 per month ($12,276 per year). Like Ozempic, sometimes prescribed off-label for weight loss.
• Saxenda (liraglutide 3.0 mg): Approximately $1,349 per month ($16,188 per year). Despite being the least effective of the three for weight loss, Saxenda carries the same list price as Wegovy.

Manufacturers offer savings programs that can reduce costs significantly for commercially insured patients. The Lilly Zepbound savings program has been particularly aggressive, offering the medication for as low as $25 per month for eligible patients with commercial insurance.

Compounded Pricing (Semaglutide vs Tirzepatide)

Compounded versions represent a significant cost savings and are a major access pathway for patients who cannot afford or access brand-name products:

• Compounded semaglutide: Typically $150-400 per month, depending on the dose, compounding pharmacy, and provider platform. At FormBlends, our compounded semaglutide program provides physician-supervised treatment at a fraction of brand-name cost. Semaglutide is the most widely compounded GLP-1 medication with the most established compounding infrastructure.
• Compounded tirzepatide: Typically $200-500 per month. Compounded tirzepatide is available through some providers, including FormBlends' tirzepatide program, but availability is more limited than compounded semaglutide due to the more complex peptide synthesis and the evolving regulatory space around tirzepatide compounding.
• Compounded liraglutide: Approximately $200-450 per month. Less commonly compounded due to lower demand (patients generally prefer the more effective newer medications) and the need for daily injections making per-injection cost higher.

Important note about compounding: compounded medications are not FDA-approved finished drug products. They are prepared by licensed pharmacies under the authority of Section 503A (patient-specific) or 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act. Quality, purity, and potency can vary between pharmacies, making the choice of provider and pharmacy critically important. Always work with providers who use verified, inspected, and licensed compounding pharmacies.

Insurance Coverage Differences

Insurance coverage for GLP-1 medications varies enormously by plan, employer, state, and diagnosis:

• For type 2 diabetes (Ozempic, Mounjaro, Victoza): Coverage is relatively broad. Most commercial plans and Medicare Part D cover at least one GLP-1 for diabetes, though prior authorization is common. Tirzepatide (Mounjaro) may face more formulary restrictions as a newer agent.
• For weight loss (Wegovy, Zepbound, Saxenda): Coverage is much more limited. Many commercial plans and most Medicare Part D plans do not cover anti-obesity medications. The space is improving slowly, with more employers adding weight loss medication coverage, but gaps remain significant.

Cost Per Pound Lost Analysis

Looking at cost-effectiveness provides another lens for comparison. Using brand-name pricing and average clinical trial weight loss for a 220-pound (100 kg) patient over 12 months:

• Semaglutide (Wegovy): $16,188 annual cost / 33 lbs lost = approximately $491 per pound
• Tirzepatide (Zepbound): $12,708 annual cost / 46 lbs lost = approximately $276 per pound
• Liraglutide (Saxenda): $16,188 annual cost / 17.6 lbs lost = approximately $920 per pound

Using compounded pricing (mid-range estimates):

• Compounded semaglutide: $3,300 annual cost / 28 lbs = approximately $118 per pound
• Compounded tirzepatide: $4,200 annual cost / 39 lbs = approximately $108 per pound

Note: These calculations use clinical trial weight loss estimates adjusted for real-world effectiveness. Actual cost-per-pound varies enormously based on individual response, actual medication cost after insurance or discounts, and the time frame analyzed.

Annual Total Cost Comparison

---

Insurance and Access Comparison

Access to GLP-1 medications remains one of the most frustrating aspects of treatment for many patients. Insurance coverage is inconsistent, prior authorization processes are burdensome, and the space changes frequently. Here is what you need to know as of early 2026.

Which Medications Are Easier to Get Covered

In general, coverage availability follows this hierarchy:

1. GLP-1 medications for type 2 diabetes (Ozempic, Mounjaro, Victoza) have the broadest coverage. Most commercial plans and Medicare Part D cover at least one option, though formulary position and tier vary.
2. Semaglutide for weight loss (Wegovy) has moderate coverage. As the first FDA-approved once-weekly GLP-1 for weight management and with growing cardiovascular benefit data (SELECT trial), it has gained formulary position with many commercial plans. Coverage is still denied by many self-insured employer plans and most Medicare Part D plans.
3. Tirzepatide for weight loss (Zepbound) is gaining coverage but as a newer entrant, faces more restrictions. Some plans added it quickly due to competitive pressure from Wegovy, while others have been slower to adopt it.
4. Liraglutide for weight loss (Saxenda) has been available the longest but faces similar coverage barriers. Some plans cover Saxenda but not Wegovy or Zepbound, creating situations where the least effective option is the only one available through insurance.

Prior Authorization Differences

Nearly all insurance plans require prior authorization for GLP-1 medications for weight management. Common requirements include:

• BMI threshold: Most plans require BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea).
• Documentation of previous weight loss attempts: Many plans require evidence of structured diet and exercise programs or other weight loss interventions within the past 6-12 months.
• Step therapy: Some plans require failure of one medication before approving another. This may mean trying liraglutide before being approved for semaglutide, or trying semaglutide before tirzepatide.
• Ongoing weight loss requirements: Some plans require demonstration of at least 5% weight loss within the first 6 months to continue coverage.

Prior authorization processing typically takes 5-14 business days. Appeals, if needed, can take an additional 2-4 weeks. Your provider's office handles most of the paperwork, but understanding the requirements helps you prepare the necessary documentation in advance.

Step Therapy Requirements

Step therapy policies require trying one medication before the plan will cover a preferred (usually more expensive) alternative. Common step therapy patterns:

• Some plans require trial of liraglutide (Saxenda) before covering semaglutide (Wegovy) or tirzepatide (Zepbound)
• Some plans require trial of semaglutide before covering tirzepatide, or vice versa
• For diabetes indications, plans may require metformin first, then a GLP-1, with specific GLP-1 preferences varying by formulary

Step therapy can be bypassed in some cases with documentation of medical necessity, intolerance to the step-therapy medication, or clinical contraindications. Your provider can often write a letter of medical necessity explaining why a specific medication is clinically appropriate for you.

Navigating insurance coverage for GLP-1 medications can be frustrating, but several strategies can improve your chances of approval:

• Document everything: Keep records of your weight history, previous weight loss attempts (commercial programs, dietitian visits, exercise programs), comorbidities related to your weight, and any previous medication trials. Insurance companies are more likely to approve coverage when there is thorough documentation.
• Ask about formulary alternatives: If your preferred medication is not covered, ask your provider about formulary alternatives. Sometimes a different brand (e.g., Mounjaro instead of Zepbound, or Ozempic instead of Wegovy) may be covered, even if the weight-specific version is not.
• Use manufacturer savings programs: Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer manufacturer savings cards that can reduce copays significantly for commercially insured patients. Lilly has been particularly aggressive, sometimes offering Zepbound for as low as $25 per month.
• Appeal denials: First-line denial is common and does not mean final denial. Work with your provider to file an appeal with additional documentation. Many initial denials are overturned on appeal. Peer-to-peer reviews (where your doctor speaks directly with the insurance company's medical director) can be especially effective.
• Consider compounding: If insurance does not cover brand-name products and appeals are unsuccessful, compounded medications through providers like FormBlends offer a cost-effective alternative that does not require insurance involvement at all.
• Check employer benefits: Some employers are adding weight management medication coverage as part of wellness programs, recognizing the long-term cost savings from treating obesity. Ask your HR department if this benefit is available or being considered.

The insurance space is evolving rapidly. The Medicare Anti-Obesity Medication (Treat and Reduce Obesity Act) has been introduced in Congress multiple times and, if passed, would expand Medicare Part D coverage of anti-obesity medications. Several states have also passed or introduced legislation requiring commercial insurance coverage of FDA-approved weight management medications. These legislative developments could significantly improve access in the coming years.

Compounded Access for Each

Compounding provides an alternative access pathway that bypasses insurance entirely:

• Compounded semaglutide: Widely available through telehealth platforms and compounding pharmacies. The most established compounded GLP-1 with the most providers. Regulatory space is evolving - compounding has been permitted during periods when semaglutide was on the FDA drug shortage list, and availability may change as brand supply stabilizes.
• Compounded tirzepatide: Available through some providers but fewer options than semaglutide. The compounding market for tirzepatide is newer and smaller. Regulatory uncertainty around tirzepatide compounding may affect future availability.
• Compounded liraglutide: Least commonly compounded due to lower demand. Daily dosing makes it less practical for compounding economics, though some pharmacies do offer it.

---

Special Populations - Which Is Best For...

Different patient populations have different needs, and no single GLP-1 medication is universally superior across all scenarios. Here we address the most common clinical situations and which medication(s) may be most appropriate for each.

Patients with Type 2 Diabetes

For patients with both obesity and type 2 diabetes, the choice between semaglutide and tirzepatide involves weighing glucose control alongside weight loss:

• Tirzepatide demonstrated superior A1C reduction compared to semaglutide 1 mg in SURPASS-2. At the 15 mg dose, tirzepatide reduced A1C by an average of 2.30% compared to 1.86% with semaglutide 1 mg. Approximately 86-92% of tirzepatide patients achieved A1C below 7.0%, versus 79% with semaglutide. The superior weight loss with tirzepatide also contributes to improved insulin sensitivity.
• Semaglutide at 2.4 mg (Wegovy) is not formally compared to tirzepatide in published trials for diabetes specifically, but semaglutide has extensive diabetes data across the SUSTAIN and PIONEER trial programs. It is a proven, well-established option.
• Liraglutide (Victoza) remains a reasonable diabetes medication but produces less weight loss and A1C reduction than either semaglutide or tirzepatide.

For most patients with type 2 diabetes seeking both glycemic control and weight loss, tirzepatide or semaglutide are preferred over liraglutide. The choice between them depends on insurance, cost, and whether the additional A1C benefit of tirzepatide is clinically meaningful for the individual patient.

Patients with Cardiovascular Disease

For patients with established cardiovascular disease or high cardiovascular risk, the evidence clearly favors semaglutide:

• Semaglutide is the only GLP-1 medication with a completed cardiovascular outcome trial (CVOT) specifically in overweight/obese patients without diabetes. The SELECT trial enrolled 17,604 patients with established cardiovascular disease and BMI of 27 or higher, without diabetes. Over a median 33 months of follow-up, semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) - cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke - by 20% compared to placebo. This is a landmark finding that established weight-dose semaglutide as a cardiovascular protective therapy.
• Liraglutide also has cardiovascular benefit data from the LEADER trial, which showed a 13% MACE reduction in patients with type 2 diabetes and high cardiovascular risk. However, this was in a diabetes-specific population at the 1.8 mg diabetes dose.
• Tirzepatide has promising cardiovascular signals from its diabetes trials (improvements in blood pressure, lipids, inflammatory markers, and body composition), and the SURPASS-CVOT trial is ongoing. However, formal cardiovascular outcome data is not yet available. Until SURPASS-CVOT results are published, tirzepatide cannot be recommended specifically for cardiovascular risk reduction.

Bottom line for CV patients: semaglutide is the evidence-based choice until tirzepatide CVOT data becomes available.

Women with PCOS

Polycystic ovary syndrome (PCOS) is strongly associated with insulin resistance, and GLP-1 medications can be particularly beneficial in this population:

• Both semaglutide and tirzepatide are excellent choices for women with PCOS. Weight loss of 5-10% can improve menstrual regularity, reduce androgen levels, improve insulin sensitivity, and enhance fertility. The greater weight loss achievable with both medications compared to liraglutide makes them preferred.
• Tirzepatide may have a theoretical advantage due to its dual GIP/GLP-1 mechanism providing additional insulin-sensitizing effects through the GIP pathway. However, direct clinical trial data in PCOS populations is limited for tirzepatide.
• Liraglutide has been studied specifically in women with PCOS and showed improvements in hormonal parameters, menstrual regularity, and metabolic markers. It has the most PCOS-specific published data of the three.

Important consideration: GLP-1 medications should be discontinued before pregnancy. Women with PCOS who are trying to conceive should discuss timing carefully with their provider. The improved fertility from weight loss and metabolic improvement means pregnancy can occur unexpectedly.

Patients Over 60

Older adults have specific considerations including sarcopenia risk, falls, bone density, and different metabolic profiles:

• Muscle preservation is a primary concern. Weight loss in older adults accelerates age-related muscle loss, increasing fall risk and functional decline. All three medications can cause lean mass loss, but the greater weight loss from tirzepatide may amplify this concern. Resistance training and adequate protein (1.0-1.2 g/kg/day) are essential regardless of medication choice.
• Lower doses may be appropriate. Older adults may benefit from lower maintenance doses (e.g., semaglutide 1.7 mg rather than 2.4 mg, or tirzepatide 10 mg rather than 15 mg) to achieve a more moderate rate of weight loss that preserves lean mass.
• Cardiovascular benefit is particularly relevant. Semaglutide's SELECT trial data is especially valuable for older adults with cardiovascular disease, given their higher baseline cardiovascular risk.
• Liraglutide's daily dosing may be advantageous for patients who benefit from the routine of a daily medication and want finer dose control to manage weight loss rate.

Patients with Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) affects an estimated 60-70% of patients with obesity and is a significant driver of cardiovascular risk, daytime fatigue, and reduced quality of life. All GLP-1 medications improve OSA through weight loss, but tirzepatide has specific trial data:

• SURMOUNT-OSA: This dedicated trial demonstrated that tirzepatide significantly reduced the apnea-hypopnea index (AHI) in patients with moderate-to-severe OSA. At the highest dose, approximately 44-52% of patients achieved AHI below 5 (essentially OSA resolution) versus 14% with placebo. Some patients were able to discontinue CPAP therapy.
• Semaglutide: While no dedicated OSA trial has been published, sub-analyses from STEP trials show significant AHI improvements correlated with weight loss. A 15% weight loss typically reduces AHI by 50% or more.
• Liraglutide: SCALE sub-analyses showed modest AHI improvement consistent with the more modest weight loss achieved.

For patients where OSA management is a primary motivation for weight loss, tirzepatide has the strongest specific evidence, though any GLP-1 medication producing significant weight loss will improve OSA.

Patients with Non-Alcoholic Fatty Liver Disease (MASLD/NASH)

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), affect a large proportion of patients with obesity. GLP-1 medications show remarkable liver benefits:

• Semaglutide: In the Phase 2 trial for NASH, semaglutide 0.4 mg daily resolved NASH (steatohepatitis disappearance) in 59% of patients versus 17% with placebo. Liver fat reduction of approximately 60% has been demonstrated with MRI-measured liver fat fraction. A Phase 3 NASH trial (ESSENCE) is ongoing.
• Tirzepatide: The together-NASH Phase 2 trial showed NASH resolution in up to 74% of patients at the highest dose, with significant improvement in fibrosis scores. Liver fat reduction was dramatic, exceeding 50% in most patients. These results are among the most impressive liver outcomes seen with any pharmacotherapy for NASH.
• Liraglutide: The LEAN trial showed NASH resolution in 39% of patients versus 9% with placebo, establishing proof of concept for GLP-1 therapy in liver disease but with more modest results than the newer agents.

For patients with significant fatty liver disease or NASH, GLP-1 therapy may provide liver benefits that extend well beyond weight loss. The direct anti-inflammatory and metabolic effects of GLP-1 receptor activation in hepatocytes appear to contribute to liver improvement independent of weight reduction.

Patients Who Have Tried One and Plateaued

Weight loss plateaus are common with all GLP-1 medications, typically occurring between months 12 and 18. If you have plateaued on one medication, switching may restart progress:

• Semaglutide to tirzepatide: The most common switch for plateau-breaking. Adding GIP receptor activation can engage new metabolic pathways. Many patients who plateaued on semaglutide report renewed appetite suppression and continued weight loss after switching to tirzepatide.
• Tirzepatide to semaglutide: Less common but reasonable if tirzepatide side effects are limiting dose escalation, or if the patient wants to try a pure GLP-1 approach.
• Either to liraglutide: Rarely recommended for plateau-breaking given liraglutide's lower efficacy. More commonly the reverse - switching from liraglutide to semaglutide or tirzepatide for greater effect.

Before switching medications for a plateau, providers should first assess: Are you actually at your maximum tolerated dose? Is adherence consistent? Has your lifestyle strategy (diet, exercise, sleep) changed? Sometimes optimizing these factors can restart progress without a medication change.

Patients Concerned About Muscle Loss

All GLP-1 medications carry some risk of lean mass loss alongside fat loss. The concern increases with greater total weight loss:

• Body composition data from trials: In semaglutide trials, approximately 40% of weight lost was lean mass. In tirzepatide trials (SURMOUNT-1), approximately 33% was lean mass - a slightly better ratio potentially related to GIP receptor effects on body composition. Liraglutide data shows similar ratios to semaglutide.
• Mitigation strategies are the same regardless of medication: Resistance training 2-3 times per week (the single most effective intervention), protein intake of at least 1.0-1.2 g/kg ideal body weight daily, and avoiding excessively rapid weight loss through appropriate dosing.
• CagriSema (semaglutide plus cagrilintide, currently in trials) has shown promising body composition data suggesting less lean mass loss, and may become an option for muscle-conscious patients in the future.

---

Switching Between Medications

Switching GLP-1 medications is common and generally straightforward when done under medical supervision. The most frequent reasons for switching include weight loss plateaus, intolerable side effects, insurance or cost changes, and seeking greater efficacy.

Semaglutide to Tirzepatide (Dose Conversion)

This is the most commonly requested switch in current clinical practice. There is no established FDA-approved dose conversion protocol, but clinical consensus has emerged:

• Recommended approach: Stop semaglutide and begin tirzepatide at 2.5 mg the following week (on your usual injection day). This is the starting dose regardless of your previous semaglutide dose.
• Rationale: Because tirzepatide activates the GIP receptor (which semaglutide does not), patients need to acclimate to this new receptor activation. Starting at the lowest dose minimizes GI side effects from the novel mechanism.
• Titration: Follow the standard tirzepatide titration schedule (2.5 mg for 4 weeks, then 5 mg, etc.). Some providers accelerate slightly for patients switching from high-dose semaglutide, but this is not universally recommended.
• Overlap considerations: Semaglutide has a half-life of approximately 7 days, so some drug remains in your system for 5-6 weeks after the last dose. This provides transitional coverage during the early tirzepatide titration and is generally well tolerated.

Tirzepatide to Semaglutide

Less common but may be appropriate for patients who experience intolerable tirzepatide side effects, need to switch for cost or insurance reasons, or prefer a medication with established cardiovascular outcome data:

• Recommended approach: Stop tirzepatide and begin semaglutide at 0.25 mg the following week. Some providers start at 0.5 mg or even 1.0 mg for patients switching from higher tirzepatide doses, but starting low is safest.
• Accelerated titration: Because the patient has already been on a GLP-1-active medication, some providers titrate semaglutide faster than the standard schedule (e.g., 2-week steps instead of 4-week steps), provided GI tolerance is good. This is a clinical judgment call.
• Expect a transition period: Some patients experience increased appetite during the switch as they lose the GIP receptor activation component. This typically resolves once semaglutide reaches therapeutic doses.

Liraglutide to Either Semaglutide or Tirzepatide

Upgrading from liraglutide to a more effective medication is common and straightforward:

• To semaglutide: Stop liraglutide and begin semaglutide at 0.25 mg weekly. Because liraglutide has a short half-life (13 hours), there is minimal overlap. Liraglutide clears within 2-3 days. Follow the standard semaglutide titration.
• To tirzepatide: Stop liraglutide and begin tirzepatide at 2.5 mg weekly. Again, liraglutide clears quickly. Follow standard tirzepatide titration.
• GI tolerance: Patients switching from liraglutide often tolerate the first few weeks of the new medication well because they are already adapted to GLP-1 receptor activation. However, the longer-acting weekly medications produce different pharmacokinetic patterns, and some adjustment period is expected.

Switching Dose Conversion Reference Table

What to Expect When Switching

Regardless of which direction you switch, expect the following:

• Temporary increase in GI side effects: The first 2-4 weeks after switching may bring renewed nausea or other GI symptoms as your body adjusts to the new medication's pharmacokinetic profile.
• Possible temporary appetite increase: During the transition from a higher-dose to a lower starting dose, appetite suppression may briefly diminish before the new medication reaches therapeutic levels.
• New injection experience: Different pen devices feel slightly different. The KwikPen (tirzepatide) and FlexTouch (semaglutide/liraglutide) have different mechanics.
• Weight trajectory may change: Some patients experience a brief weight plateau or slight regain during the transition period before weight loss resumes on the new medication.

Washout Periods

Formal washout periods between GLP-1 medications are generally not required or recommended:

• Semaglutide to tirzepatide: No washout needed. Start tirzepatide the week after last semaglutide dose.
• Tirzepatide to semaglutide: No washout needed. Start semaglutide the week after last tirzepatide dose.
• Liraglutide to either: No washout needed. Can start the new medication 1-3 days after last liraglutide dose.
• The medications share overlapping but not identical mechanisms, and the physiological overlap during transition is generally well tolerated.

The only exception might be if the switch is being made due to a serious adverse event (e.g., pancreatitis), in which case the adverse event should fully resolve before starting any new GLP-1 medication, and some conditions may contraindicate rechallenge with any GLP-1 agent.

---

Beyond Weight Loss - Cardiovascular, Kidney, and Metabolic Benefits

GLP-1 medications are increasingly recognized as more than just weight loss drugs. Their effects on the cardiovascular system, kidneys, liver, and systemic inflammation may be as important as their effects on body weight - particularly for patients with cardiometabolic disease. These non-weight benefits differ between the three medications and are an important consideration in medication selection.

Cardiovascular Data by Medication

Semaglutide - SELECT Trial (The Gold Standard)

The SELECT trial is the most important cardiovascular study in the GLP-1 weight management space. Key findings include:

• 17,604 patients with established cardiovascular disease, BMI 27+, without diabetes
• Semaglutide 2.4 mg vs. placebo over a median 33 months
• 20% reduction in MACE (cardiovascular death, nonfatal MI, nonfatal stroke)
• Significant reductions in heart failure events and cardiovascular death
• Benefits were observed regardless of baseline BMI, age, sex, or geographic region
• The cardiovascular benefits appeared to emerge within the first 6-12 months and were sustained throughout the trial
• Benefits occurred beyond what would be expected from weight loss alone, suggesting direct cardiovascular protective effects

Based on SELECT, the FDA expanded Wegovy's indication to include cardiovascular risk reduction in patients with established cardiovascular disease and overweight/obesity. This was a milestone for the field, establishing GLP-1 therapy as a treatment for cardiovascular disease itself, not just a risk factor (obesity).

Liraglutide - LEADER Trial

The LEADER trial (9,340 patients with type 2 diabetes and high CV risk) showed a 13% reduction in MACE with liraglutide 1.8 mg (the diabetes dose) over 3.8 years. While significant, the magnitude is smaller than SELECT, and the population was different (diabetes patients, lower dose). LEADER established liraglutide as cardioprotective but does not apply to the Saxenda weight loss dose specifically.

Tirzepatide - SURPASS-CVOT (Ongoing)

The SURPASS-CVOT trial is a large cardiovascular outcome study of tirzepatide in patients with type 2 diabetes and established cardiovascular disease. Results are expected in 2026-2027. Until this trial reports, tirzepatide cannot be formally recommended for cardiovascular risk reduction, though its metabolic benefits (weight loss, glucose control, blood pressure reduction, lipid improvements) strongly suggest cardiovascular benefit. Early signals from the SURPASS diabetes trials show favorable cardiovascular risk factor profiles.

Kidney Protection Data

Chronic kidney disease (CKD) frequently co-occurs with obesity and type 2 diabetes. GLP-1 medications show renal benefits:

• Semaglutide: The FLOW trial (2024) demonstrated that semaglutide 1.0 mg reduced the risk of clinically important kidney outcomes (sustained eGFR decline of 50% or more, kidney failure, or kidney death) by 24% in patients with type 2 diabetes and CKD. This was the first dedicated renal outcome trial for semaglutide and led to the trial being stopped early for efficacy. The SELECT trial also showed renal benefits in its secondary analysis.
• Liraglutide: LEADER trial secondary analyses showed slower decline in kidney function with liraglutide, with a 22% reduction in new-onset persistent macroalbuminuria.
• Tirzepatide: Post-hoc analyses from SURPASS trials show improvements in urinary albumin-to-creatinine ratio and slower eGFR decline. Dedicated renal outcome trials are in development.

For patients with both obesity and CKD, semaglutide currently has the strongest kidney-specific evidence. However, weight loss itself improves kidney function, so all three medications provide renal benefit indirectly.

Metabolic Benefits Comparison

All three medications improve metabolic parameters beyond weight loss, but the degree varies:

• Blood pressure: All three reduce systolic blood pressure by approximately 4-6 mmHg. Tirzepatide may have a slightly greater effect at higher doses due to greater weight loss.
• Lipids: All three reduce triglycerides and improve HDL/LDL ratios. Tirzepatide shows particularly strong triglyceride reduction (potentially related to GIP effects on lipid metabolism).
• Fatty liver (MASLD/NASH): Both semaglutide and tirzepatide have shown impressive reductions in liver fat content and improvement in NASH histology in dedicated trials. Semaglutide reduced liver fat by approximately 60% in liver-focused studies. Tirzepatide showed similar or greater improvements, with a Phase 2 trial (together-NASH) showing NASH resolution in up to 74% of patients at the highest dose.
• Inflammatory markers: All three reduce C-reactive protein (CRP) and other inflammatory markers. Semaglutide showed significant CRP reduction in SELECT. This anti-inflammatory effect may contribute to cardiovascular and metabolic benefits independent of weight loss.
• Sleep apnea: Weight loss from any GLP-1 medication improves obstructive sleep apnea. The SURMOUNT-OSA trial specifically demonstrated tirzepatide's benefit in sleep apnea patients, with significant reductions in apnea-hypopnea index.

Anti-Inflammatory Effects

The anti-inflammatory properties of GLP-1 medications are an increasingly recognized benefit that may underlie many of their cardiovascular and metabolic advantages:

• GLP-1 receptors are present on immune cells, and their activation modulates inflammatory signaling pathways
• All three medications reduce CRP, IL-6, and other inflammatory biomarkers
• The anti-inflammatory effects appear to be partially independent of weight loss, suggesting direct receptor-mediated anti-inflammatory action
• This may explain why cardiovascular benefits in SELECT were observed relatively early (within months) and were greater than expected from weight loss alone
• Ongoing research is exploring whether GLP-1 medications may benefit other inflammatory conditions, including autoimmune diseases, neuroinflammation, and chronic pain conditions

Long-Term Treatment Considerations

GLP-1 therapy for weight management is increasingly understood as a long-term or chronic treatment, similar to medications for hypertension or hyperlipidemia. Several long-term considerations affect medication choice:

• Treatment duration expectations: Most patients will need to continue GLP-1 therapy indefinitely to maintain weight loss. Discontinuation studies (STEP 4, SURMOUNT-4) consistently show significant weight regain within 12 months of stopping. Setting the expectation of long-term treatment from the outset helps with adherence and reduces frustration when weight management requires ongoing medication.
• Dose optimization over time: Some patients find that their optimal maintenance dose differs from the maximum dose. After reaching their weight loss goal or plateau, some providers reduce the dose to the lowest effective level that maintains results. This reduces cost, minimizes side effects, and may improve long-term adherence. For example, some patients maintain results on semaglutide 1.7 mg rather than 2.4 mg, or tirzepatide 10 mg rather than 15 mg.
• Drug holidays and interruptions: Planned or unplanned treatment interruptions (supply issues, cost changes, travel, pregnancy planning) are common in real-world practice. Understanding that some weight regain during interruptions is normal and that retreatment typically produces renewed weight loss helps patients manage these situations without discouragement.
• Evolving treatment space: Patients starting treatment today should know that more effective medications may become available in 2-3 years. This is not a reason to delay treatment - the health benefits of weight loss now are valuable regardless of future options - but it does mean that treatment plans may evolve over time as new options become available.
• Combination approaches: Some providers are beginning to explore combination strategies: GLP-1 medications plus metformin, SGLT2 inhibitors, or low-dose naltrexone/bupropion. While evidence for these combinations is still emerging, the future of obesity pharmacotherapy may involve personalized multi-drug regimens similar to how hypertension is managed with combination therapy.

The recognition of obesity as a chronic disease requiring long-term treatment represents a fundamental shift in how both the medical community and patients approach weight management. GLP-1 medications are not temporary fixes but ongoing therapeutic tools, and choosing the right one involves considering not just short-term efficacy but long-term sustainability, cost, and alignment with your health goals.

---

The Decision Framework - How to Choose

After reviewing all the data, the question remains: which medication should you choose? The answer depends on your specific circumstances. Here is a structured decision framework organized by priority.

If Maximum Weight Loss Is Your Priority → Tirzepatide

If your primary goal is to lose as much weight as possible, tirzepatide at the 10 mg or 15 mg dose produces the highest average weight loss of any available medication. The SURMOUNT data showing 20-22% average body weight loss (and over 25% when combined with intensive behavioral therapy) represents the current ceiling for pharmaceutical weight management. Approximately 57% of patients at the highest dose lost 20% or more of their body weight - results previously seen only with bariatric surgery.

However, consider that the 5 mg dose of tirzepatide produces results comparable to semaglutide 2.4 mg (~15%). Not everyone needs to reach 15 mg. Your provider will help determine the optimal dose based on your response and tolerance.

If Long Track Record Matters → Semaglutide

If you value extensive published research, established safety data, and proven cardiovascular benefits, semaglutide (Wegovy) has the most comprehensive evidence base of any GLP-1 medication for weight management. The STEP program, SELECT cardiovascular trial, FLOW kidney trial, and years of real-world experience provide a level of confidence that newer medications have not yet achieved. Semaglutide has been used by millions of patients worldwide, and its safety profile is well characterized.

If Cost Is Primary Concern → Compare Compounded Options

For uninsured patients or those whose insurance does not cover GLP-1 medications for weight loss, compounded medications offer the most affordable path. Compounded semaglutide is generally the least expensive option at $150-400 per month, with the widest availability. Compounded tirzepatide costs slightly more at $200-500 per month but may offer better value per pound lost. Both are available through providers like FormBlends at a fraction of brand-name pricing.

At the brand-name level, Zepbound (tirzepatide) has a lower list price than Wegovy (semaglutide) and Eli Lilly's direct-to-consumer savings programs have been particularly aggressive.

If You Have Diabetes → Consider Both Semaglutide and Tirzepatide

Both are excellent options for patients with type 2 diabetes. Tirzepatide has a slight edge in A1C reduction based on SURPASS-2, but semaglutide has more extensive long-term diabetes data. Insurance formulary position, prior authorization requirements, and your provider's experience with each medication may be the deciding factors.

If You Want Oral → Rybelsus Currently, Oral Options Expanding

Oral semaglutide (Rybelsus) is the only currently available oral GLP-1 option, though it is approved for diabetes only at the current doses. Higher-dose oral semaglutide for weight loss is expected to gain FDA approval. Orforglipron, a next-generation oral GLP-1, is in late-stage development. If avoiding injections is your top priority, oral options are limited now but expanding rapidly.

Decision Framework Table

Decision Tree Summary

Here is a simplified decision pathway to discuss with your healthcare provider:

1. Do you have established cardiovascular disease? → Start with semaglutide (strongest CV evidence)
2. Is maximum weight loss the top priority? → Consider tirzepatide first
3. Does insurance cover one but not the other? → Choose the covered medication (both are highly effective)
4. Are you paying out of pocket? → Compare compounded semaglutide vs. tirzepatide pricing through your provider
5. Have you tried one and plateaued? → Switch to the other (semaglutide to tirzepatide or vice versa)
6. Do you strongly prefer daily injections or need very granular dose control? → Consider liraglutide
7. Unsure or first-time? → Either semaglutide or tirzepatide are excellent starting points; let insurance, cost, and provider recommendation guide you

---

Pipeline Medications - What Is Coming Next

The GLP-1 and incretin-based therapy space is evolving rapidly. Several next-generation medications in clinical development may surpass current options in efficacy, convenience, or both. Understanding the pipeline helps contextualize your current choices and set expectations for the near future.

Retatrutide (Triple Agonist)

Retatrutide (Eli Lilly, also known as LY3437943) is a triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors. The addition of glucagon receptor agonism is the key innovation:

• Mechanism: Glucagon receptor activation increases energy expenditure, promotes fat oxidation, and reduces liver fat. Combined with GIP and GLP-1 effects, this creates a three-pronged approach to weight management.
• Phase 2 data: In a 48-week Phase 2 trial, retatrutide at the highest dose produced an average of 24.2% weight loss - exceeding tirzepatide 15 mg results. Some participants lost over 30% of their body weight.
• Phase 3 status: Multiple Phase 3 trials are underway, with results expected in 2026-2027. If confirmed, retatrutide could become the most effective pharmaceutical weight loss agent available.
• Potential concerns: The glucagon component could theoretically raise blood glucose, though this appears to be offset by the GIP and GLP-1 components in trial data so far. Liver safety monitoring will be important given glucagon's hepatic effects.

Orforglipron (Oral, Once-Daily)

Orforglipron (Eli Lilly) is a small-molecule, non-peptide oral GLP-1 receptor agonist that represents a potential breakthrough in oral GLP-1 therapy:

• Key advantage: Unlike oral semaglutide (Rybelsus), orforglipron does not require SNAC coformulation or strict fasting conditions. It can be taken with or without food, making it much more practical for daily use.
• Phase 2 data: In a 36-week Phase 2 trial, orforglipron produced up to 14.7% weight loss, comparable to injectable semaglutide.
• Phase 3 status: Multiple Phase 3 trials (ACHIEVE program) are ongoing for both type 2 diabetes and weight management. Results are expected beginning in 2026.
• Potential impact: If approved, orforglipron could dramatically expand GLP-1 access by eliminating the injection barrier entirely. Many patients who refuse injectable therapy would consider an oral pill.

Survodutide

Survodutide (Boehringer Ingelheim) is a dual GLP-1/glucagon receptor agonist (different from tirzepatide, which is GIP/GLP-1):

• Mechanism: Combines GLP-1 appetite suppression with glucagon-mediated energy expenditure increases and liver fat reduction.
• Phase 2 data: Showed up to 19.5% weight loss at 46 weeks in the SYNCHRONIZE-1 trial, plus dramatic reductions in liver fat (up to 67%) making it particularly promising for NASH/MASLD.
• Phase 3 status: Phase 3 trials for both obesity and NASH are underway.
• NASH focus: Survodutide may be positioned primarily as a NASH treatment with weight loss as a co-benefit, given its exceptional liver fat reduction data.

CagriSema (Semaglutide + Cagrilintide)

CagriSema (Novo Nordisk) combines semaglutide with cagrilintide, a long-acting amylin analog:

• Mechanism: Amylin is a hormone co-secreted with insulin that promotes satiety, slows gastric emptying, and suppresses glucagon. By combining amylin and GLP-1 receptor activation, CagriSema targets complementary appetite pathways.
• Phase 3 data: The REDEFINE program is reporting results. CagriSema has shown weight loss of approximately 22-24% in Phase 2/3 data, with potentially favorable body composition effects (better lean mass preservation compared to semaglutide alone).
• Potential advantage: The lean mass preservation signal, if confirmed, would be clinically significant, particularly for older patients and those concerned about sarcopenia.
• Competitive positioning: CagriSema represents Novo Nordisk's answer to Lilly's tirzepatide, aiming to match or exceed its efficacy while building on the established semaglutide platform.

The pipeline medications suggest that within 2-3 years, patients may have access to agents producing 25-30% weight loss, oral options rivaling injectable efficacy, and better body composition preservation. However, today's choices - semaglutide, tirzepatide, and liraglutide - remain excellent and well-proven options for patients ready to start treatment now.

Pemvidutide and Other Dual Agonists

Beyond the major pipeline candidates, several other medications are in development that could further expand the GLP-1 treatment space:

• Pemvidutide (Altimmune): A GLP-1/glucagon dual receptor agonist being developed primarily for NASH/MASLD and obesity. Phase 2 data showed approximately 10-15% weight loss over 48 weeks with notable liver fat reduction. While weight loss is more modest than retatrutide, the liver-focused profile may position it for the NASH population specifically.
• Maritide (Amgen): An antibody-peptide conjugate combining GLP-1 receptor agonism with GIP receptor antagonism (the opposite of tirzepatide's GIP agonism). Phase 2 data showed significant weight loss with monthly dosing - a potential convenience advantage. The once-monthly injection schedule could improve adherence significantly compared to weekly or daily options.
• Higher-dose oral semaglutide (Novo Nordisk): Oral semaglutide at 25 mg and 50 mg daily has completed Phase 3 trials for weight management (OASIS program). The 50 mg dose showed approximately 15-17% weight loss, approaching injectable semaglutide results. FDA submission is expected, and approval would provide the first oral GLP-1 specifically indicated for weight loss.

The pipeline activity underscores the enormous investment and innovation happening in the metabolic disease space. For patients starting treatment today, the current options - semaglutide, tirzepatide, and liraglutide - are highly effective and well-studied. Pipeline medications represent the next wave but are years from widespread availability. The best medication for you is the one you can access, afford, and take consistently now, with the understanding that your treatment plan may evolve as new options reach the market.

---

Common Myths and Misconceptions About GLP-1 Comparisons

The rapid growth of GLP-1 medications has spawned numerous misconceptions, particularly in social media and unvetted online forums. Clearing up these myths helps patients make better-informed decisions.

Myth: Tirzepatide is just a stronger version of semaglutide.

This is one of the most common misconceptions. Tirzepatide is not simply semaglutide at a higher dose or with greater potency. It is a fundamentally different molecule that activates two receptors (GIP and GLP-1) rather than one. The additional GIP receptor activation engages different biological pathways in fat tissue, the brain, and the pancreas. This mechanistic difference explains both its greater efficacy and its somewhat different side effect profile. Patients who do not respond to semaglutide may respond to tirzepatide precisely because of this different mechanism, and vice versa. Thinking of them as two distinct therapeutic strategies, rather than weak vs. strong versions of the same approach, is more accurate.

Myth: The medication with the highest clinical trial numbers is always the best choice.

Clinical trial averages mask enormous individual variation. In every GLP-1 trial, some patients lose 25-30% of body weight while others lose less than 5% on the same medication and dose. Your individual response depends on genetics, metabolic health, concurrent medications, diet, activity level, adherence, sleep quality, stress, and other factors that vary from person to person. The best medication for you is the one that works well in your body, that you can afford, that you tolerate, and that you can consistently take long-term. For some patients, that will be semaglutide; for others, tirzepatide; and for a smaller group, liraglutide.

Myth: GLP-1 medications are just appetite suppressants.

While appetite suppression is a major mechanism, GLP-1 medications have wide-ranging metabolic effects that extend far beyond simply making you eat less. They improve insulin sensitivity, reduce inflammation (CRP, IL-6), improve cardiovascular outcomes (SELECT trial), protect kidney function (FLOW trial), reduce liver fat (NASH trials), improve blood pressure, improve lipid profiles, and may have neuroprotective effects (currently being studied in Alzheimer's disease trials). Calling them appetite suppressants is like calling statins cholesterol pills - technically partially correct but missing the broader therapeutic picture.

Myth: You will definitely regain all the weight when you stop.

While weight regain after discontinuation is a real concern, the framing of inevitable complete regain is inaccurate. Studies show that patients who have adopted healthier eating patterns, increased physical activity, and built sustainable habits during GLP-1 therapy retain some of those behavior changes even after stopping medication. The STEP 1 extension showed approximately two-thirds of weight loss was regained within one year, meaning one-third was maintained without medication. Patients who combine GLP-1 therapy with meaningful lifestyle changes are more likely to maintain a larger portion of their weight loss. Additionally, many patients and providers now view GLP-1 therapy as long-term treatment, similar to blood pressure medication, eliminating the question of what happens when you stop.

Myth: Compounded GLP-1 medications are unsafe or ineffective.

The quality of compounded medications depends entirely on the compounding pharmacy and the oversight of the prescribing provider. Compounded semaglutide and tirzepatide from licensed, inspected 503A or 503B pharmacies, prescribed by licensed physicians through reputable platforms, can be effective alternatives to brand-name products. The key variables are pharmacy accreditation, third-party potency testing, proper sterile compounding procedures, and cold-chain storage and shipping. Compounded medications are not FDA-approved finished drug products, and patients should understand this distinction, but characterizing all compounded medications as unsafe is inaccurate and denies access to patients who cannot afford brand-name pricing.

Myth: Higher doses always produce better results.

While there is generally a dose-response relationship with GLP-1 medications, not all patients need the maximum dose to achieve meaningful results. Some patients reach their weight loss goals or a satisfactory plateau at intermediate doses (semaglutide 1.7 mg, tirzepatide 10 mg) with fewer side effects and lower cost. Pushing to the maximum dose when an intermediate dose is working well increases side effects without guaranteed additional benefit. Your provider should individualize your dose based on your response, tolerance, and goals, not automatically titrate everyone to the highest available dose.

Frequently Asked Questions

Is tirzepatide better than semaglutide for weight loss?

In clinical trials, tirzepatide produced higher average weight loss than semaglutide. The SURMOUNT-1 trial showed 20.9% average body weight loss with tirzepatide at the highest dose, compared to 14.9% with semaglutide 2.4 mg in STEP 1. However, individual responses vary significantly, and factors like insurance coverage, side effect tolerance, and your specific health profile all influence which medication is best for you. Both are highly effective GLP-1 medications, and some patients respond better to one than the other regardless of the average trial data.

What is the difference between Ozempic and Mounjaro?

Ozempic contains semaglutide, a pure GLP-1 receptor agonist made by Novo Nordisk, while Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly. Both are FDA-approved for type 2 diabetes. Their weight-loss counterparts are Wegovy (semaglutide) and Zepbound (tirzepatide). Mounjaro/tirzepatide has shown slightly higher average weight loss in clinical trials, but both are effective. They also use different injection devices and have different titration schedules.

Can you switch from semaglutide to tirzepatide?

Yes, you can switch from semaglutide to tirzepatide under medical supervision. Most providers recommend starting tirzepatide at 2.5 mg weekly regardless of your previous semaglutide dose, then titrating up following the standard schedule. No washout period is typically required. You may experience a temporary increase in GI side effects during the transition as your body adjusts to the dual-receptor mechanism.

Which GLP-1 medication has the fewest side effects?

All GLP-1 medications share a similar side effect profile, primarily gastrointestinal symptoms like nausea, vomiting, and diarrhea. Tirzepatide reported lower nausea rates in trials (31% vs. 44% for semaglutide), though this comparison across different trials has limitations. Liraglutide tends to have slightly milder peak GI side effects due to its daily dosing pattern and lower peak drug levels but requires 365 injections per year. Most side effects with all three medications are dose-dependent, temporary, and manageable with proper titration.

How much does semaglutide cost compared to tirzepatide?

Brand-name semaglutide (Wegovy) costs approximately $1,349 per month, while brand-name tirzepatide (Zepbound) costs approximately $1,059 per month. Compounded versions are significantly cheaper: compounded semaglutide ranges from $150-400 per month and compounded tirzepatide from $200-500 per month, depending on dose and provider. Insurance coverage varies widely for both medications.

Is Wegovy or Zepbound better for weight loss?

Zepbound (tirzepatide) has demonstrated slightly higher average weight loss in clinical trials compared to Wegovy (semaglutide). In SURMOUNT-1, tirzepatide at 15 mg produced 20.9% body weight loss over 72 weeks, while semaglutide at 2.4 mg in STEP 1 produced 14.9% over 68 weeks. However, these were separate trials with different populations. A direct head-to-head trial of maximum weight loss doses has not been published. Both are considered among the most effective weight loss medications ever developed.

Why would a doctor prescribe liraglutide instead of semaglutide or tirzepatide?

Doctors may prescribe liraglutide (Saxenda) for patients who prefer daily dosing for more flexible dose control, those who experienced intolerable side effects with weekly medications, patients who need a medication with a longer safety track record (FDA-approved since 2014), those whose insurance covers liraglutide but not the other options, or adolescents (Saxenda is approved for ages 12+). Some providers also use liraglutide as a transitional medication before moving to a weekly agent.

What is the most effective GLP-1 for type 2 diabetes?

Both semaglutide and tirzepatide are highly effective for type 2 diabetes. Tirzepatide showed superior A1C reduction in the SURPASS-2 trial, with up to 2.3% A1C reduction at the highest dose versus approximately 1.9% with semaglutide 1 mg. Both are recommended as second-line therapy after metformin. For patients needing both glucose control and maximum weight loss, tirzepatide may have a slight advantage, though semaglutide has more extensive long-term diabetes data.

Do you need to stop semaglutide before starting tirzepatide?

No, a formal washout period is typically not required. Most providers recommend stopping semaglutide and starting tirzepatide at 2.5 mg the following week, on your usual injection day. Since semaglutide has a half-life of about one week, there will be some overlapping drug exposure for a few weeks, which is generally well-tolerated and provides transitional coverage during early tirzepatide titration.

Can you take semaglutide and tirzepatide together?

No, semaglutide and tirzepatide should not be taken together. Both activate the GLP-1 receptor, so combining them would cause overlapping effects and significantly increase the risk of severe gastrointestinal side effects, persistent nausea, and potentially dangerous drops in blood sugar. If one medication is not providing adequate results, your provider may recommend switching to the other or adjusting your dose rather than combining them.

Which GLP-1 causes the least nausea?

In clinical trials, tirzepatide reported lower nausea rates (25-31% depending on dose) compared to semaglutide (44%) and liraglutide (39%). However, these numbers come from different trials. In the one head-to-head comparison (SURPASS-2), tirzepatide and semaglutide had relatively similar nausea rates. Slow titration, taking the medication with food, eating smaller meals, and staying hydrated can reduce nausea with any GLP-1. Liraglutide's daily dosing allows the finest dose adjustments for managing nausea.

How long does it take to see results with GLP-1 medications?

Most patients notice appetite reduction within the first 1-2 weeks and measurable weight loss within 4-8 weeks. However, the initial titration period (5 weeks for liraglutide, 16-20 weeks for semaglutide and tirzepatide) involves gradually increasing doses, so maximum weight loss rates occur after reaching the target dose. The most significant results typically appear between months 3 and 12, with continued but slower weight loss through months 12-18. Weight loss typically plateaus between months 15-18 with continued treatment.

Is compounded semaglutide as effective as Wegovy?

Compounded semaglutide contains the same active ingredient as Wegovy and, when properly prepared by a licensed pharmacy, should produce similar effects. However, compounded medications are not FDA-approved finished drug products and do not undergo the same batch-level testing as brand-name products. The key is working with a reputable provider that uses licensed 503A or 503B pharmacies with rigorous quality controls, third-party testing, and proper cold-chain handling.

What happens when you stop taking GLP-1 medications?

Research consistently shows that most patients regain a significant portion of lost weight within 1-2 years of stopping GLP-1 medications, regardless of which one they used. The STEP 1 extension study showed approximately two-thirds of weight loss was regained within one year of stopping semaglutide. SURMOUNT-4 showed similar patterns with tirzepatide. This is why many providers view GLP-1 therapy as long-term or potentially lifelong treatment, similar to blood pressure medication, rather than a short-term intervention.

Are there oral versions of these GLP-1 medications?

Currently, oral semaglutide (Rybelsus) is available but only FDA-approved for type 2 diabetes at doses up to 14 mg daily. Higher-dose oral semaglutide (25 mg and 50 mg) for weight loss has completed Phase 3 trials and is expected to gain FDA approval for weight management. Oral tirzepatide is in clinical development. Orforglipron (Eli Lilly), a new oral small-molecule GLP-1 agonist, is in Phase 3 trials and may offer a more convenient oral option without the strict dosing requirements of Rybelsus.

Which GLP-1 is best for someone with heart disease?

Semaglutide currently has the strongest cardiovascular evidence. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease. Liraglutide showed a 13% MACE reduction in the LEADER trial (diabetes population). Tirzepatide cardiovascular outcome data from SURPASS-CVOT is expected in 2026-2027. For patients with existing heart disease, semaglutide is the evidence-based choice.

How do GLP-1 medications affect muscle mass?

All GLP-1 medications can cause some loss of lean muscle mass along with fat loss, which is a concern with any significant weight loss. Studies show approximately 25-40% of weight lost may come from lean mass. Tirzepatide may have a slightly better fat-to-lean loss ratio based on SURMOUNT body composition data. Strategies to minimize muscle loss include resistance training at least 2-3 times per week, adequate protein intake (1.0-1.2 g/kg of ideal body weight daily), and gradual rather than rapid weight loss.

Can I use GLP-1 medications if I have PCOS?

Yes, GLP-1 medications can be particularly beneficial for women with PCOS. Weight loss from GLP-1 therapy can improve insulin resistance, reduce androgen levels, restore menstrual regularity, and improve fertility. Both semaglutide and tirzepatide have shown benefits in this population. However, GLP-1 medications should be discontinued before pregnancy, and women with PCOS who may become pregnant should discuss this timing with their provider.

What is the difference between Saxenda and Wegovy?

Saxenda contains liraglutide (3.0 mg daily injection) and Wegovy contains semaglutide (2.4 mg weekly injection). Wegovy produces significantly more weight loss, averaging 15-17% versus 5-8% with Saxenda. However, Saxenda requires daily injection which allows more granular dose control, has a longer safety track record since 2014, and is approved for adolescents aged 12+. Wegovy is generally preferred for efficacy in adults.

How do I know which GLP-1 is right for me?

The right GLP-1 medication depends on multiple factors: your weight loss goals, existing health conditions (especially cardiovascular disease or diabetes), insurance coverage and cost considerations, preference for injection frequency, and previous medication experience. A healthcare provider can evaluate your complete medical history and help you choose. The good news is that multiple effective options exist, and if one does not work well for you, switching to another is straightforward.

Are newer GLP-1 medications always better than older ones?

Not necessarily. While newer medications like tirzepatide show higher average weight loss numbers in trials, older options like liraglutide have longer safety track records, more real-world experience, and may be the right choice for specific patients. Individual response varies significantly - some patients who do not respond well to tirzepatide may do well on semaglutide, and vice versa. The best medication is the one that works for your body, fits your budget, and you can consistently take long-term.

---

Getting Started with GLP-1 Therapy at FormBlends

If you have read this guide and are ready to explore GLP-1 therapy, FormBlends provides physician-supervised access to both compounded semaglutide and compounded tirzepatide at a fraction of brand-name cost. Our medical team will help you determine which medication is most appropriate based on your health profile, goals, and preferences.

Our process includes:

• Comprehensive medical evaluation by a licensed physician
• Personalized medication selection based on your health history, goals, and preferences
• Individualized dosing and titration plan
• Ongoing provider access for dose adjustments, side effect management, and questions
• Compounded medications from licensed, inspected pharmacies
• Nutritional and lifestyle guidance to maximize your results

Whether you choose semaglutide, tirzepatide, or are unsure which is right for you, our providers will guide you through the decision with the same data-driven, objective approach presented in this guide.

Start Your Free Consultation

---

References and Further Reading

• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. (STEP 1)
• Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021;325(14):1403-1413.
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021;325(14):1414-1425.
• Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091.
• Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes (STEP 8). JAMA. 2022;327(2):138-150.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1)
• Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
• Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). N Engl J Med. 2024;390(6):514-525.
• Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.
• Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). N Engl J Med. 2015;373(1):11-22.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
• Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311-322.
• Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121.
• Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526.
• Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888.

---

Medical Disclaimer: This guide is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. The information in this guide reflects published research and clinical experience as of March 2026 and may not reflect the most recent developments. Individual results with GLP-1 medications vary significantly based on genetics, adherence, lifestyle, and other factors. No specific outcome is guaranteed. FormBlends provides physician-supervised telehealth services - all prescribing decisions are made by licensed healthcare providers based on individual patient evaluation. Compounded medications are prepared by licensed pharmacies but are not FDA-approved finished drug products. Never share prescription medications with others. This guide presents clinical data objectively and does not constitute an endorsement of one medication over another.